Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AVIDITY BIOSCIENCES, INC.

(RNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
21.92(c) 22.33(c) 22.79(c) 24.15(c) 23.2(c) Last
345 706 353 573 281 569 284 068 488 863 Volume
-9.50% +1.87% +2.06% +5.97% -3.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 9,51 M - -
Net income 2021 -112 M - -
Net cash position 2021 393 M - -
P/E ratio 2021 -8,51x
Yield 2021 -
Sales 2022 6,58 M - -
Net income 2022 -149 M - -
Net cash position 2022 305 M - -
P/E ratio 2022 -7,27x
Yield 2022 -
Capitalization 1 088 M 1 088 M -
EV / Sales 2021 73,0x
EV / Sales 2022 119x
Nbr of Employees 71
Free-Float 91,2%
More Financials
Company
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company focuses on oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC), designed to overcome the limitations of oligonucleotide-based therapies to treat a range of serious diseases. It utilizes its AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and... 
Sector
Pharmaceuticals
Calendar
12/09 | 11:00am
More about the company
Ratings of Avidity Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about AVIDITY BIOSCIENCES, INC.
11/09Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights ..
PU
11/09AVIDITY BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
11/09Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/09Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
PR
11/04Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC&tr..
PR
11/04Avidity Biosciences, Inc. Announces First Person Dose with an Antibody Oligonucleotide ..
CI
11/02Avidity Biosciences to Participate in Upcoming Investor Conferences
PR
11/02Certain Common Stock of Avidity Biosciences, Inc. are subject to a Lock-Up Agreement En..
CI
11/02Certain Options of Avidity Biosciences, Inc. are subject to a Lock-Up Agreement Ending ..
CI
10/18AVIDITY BIOSCIENCES : Says FDA Grants its AOC 1001 Myotonic Dystrophy Type 1 Treatment Fas..
MT
10/18AVIDITY BIOSCIENCES : FDA Grants Fast Track Designation to AOC 1001 for the Treatment of M..
PR
10/18Avidity Biosciences Lead Program Gets FDA Fast-Track Designation
DJ
09/07AVIDITY BIOSCIENCES : Evercore ISI Starts Avidity Biosciences at Outperform with $50 Price..
MT
09/01Health Care Stocks Reverse Losses as Biotechs Rise
MT
09/01Top Midday Decliners
MT
More news
News in other languages on AVIDITY BIOSCIENCES, INC.
10/18Avidity Biosciences déclare que la FDA accorde à son traitement de la dystrophie myoton..
09/01Les actions du secteur de la santé inversent leurs pertes alors que les biotechnologies..
09/01Les actions du secteur de la santé en baisse, les biotechs s'efforcent de limiter les b..
09/01Les actions d'Avidity Biosciences chutent après le départ du médecin-chef
08/24Le candidat au traitement de la dystrophie myotonique d'Avidity Biosciences obtient la ..
More news
Analyst Recommendations on AVIDITY BIOSCIENCES, INC.
More recommendations
Chart AVIDITY BIOSCIENCES, INC.
Duration : Period :
Avidity Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVIDITY BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 23,20 $
Average target price 46,40 $
Spread / Average Target 100%
EPS Revisions
Managers and Directors
Sarah Boyce President, Chief Executive Officer & Director
Michael F. MacLean Chief Financial & Accounting Officer
Troy E. Wilson Non-Executive Chairman
Arthur A. Levin Chief Scientific Officer
W. Michael Flanagan Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
AVIDITY BIOSCIENCES, INC.-9.09%1 088
CSL LIMITED5.12%95 233
WUXI BIOLOGICS (CAYMAN) INC.0.39%56 209
SAMSUNG BIOLOGICS CO.,LTD.8.96%50 311
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%32 892